Free Trial

Apogee Therapeutics (APGE) Competitors

Apogee Therapeutics logo
$55.15 +1.75 (+3.28%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$56.67 +1.52 (+2.76%)
As of 10/17/2025 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

APGE vs. MRUS, RNA, GRFS, CYTK, RYTM, ABVX, CRSP, NUVL, AXSM, and LEGN

Should you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Merus (MRUS), Avidity Biosciences (RNA), Grifols (GRFS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), CRISPR Therapeutics (CRSP), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.

Apogee Therapeutics vs. Its Competitors

Merus (NASDAQ:MRUS) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Apogee Therapeutics has a net margin of 0.00% compared to Merus' net margin of -685.64%. Apogee Therapeutics' return on equity of -34.65% beat Merus' return on equity.

Company Net Margins Return on Equity Return on Assets
Merus-685.64% -50.28% -42.00%
Apogee Therapeutics N/A -34.65%-32.76%

Apogee Therapeutics has lower revenue, but higher earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merus$36.13M198.63-$215.33M-$5.50-17.25
Apogee TherapeuticsN/AN/A-$182.15M-$4.13-13.35

Merus has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500.

96.1% of Merus shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 3.7% of Merus shares are held by insiders. Comparatively, 42.8% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Merus currently has a consensus target price of $93.12, indicating a potential downside of 1.87%. Apogee Therapeutics has a consensus target price of $92.63, indicating a potential upside of 67.95%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Apogee Therapeutics is more favorable than Merus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merus
1 Sell rating(s)
14 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.16
Apogee Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70

In the previous week, Merus had 8 more articles in the media than Apogee Therapeutics. MarketBeat recorded 9 mentions for Merus and 1 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.14 beat Merus' score of -0.02 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Merus
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
3 Very Negative mention(s)
Neutral
Apogee Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Apogee Therapeutics beats Merus on 12 of the 15 factors compared between the two stocks.

Get Apogee Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APGE vs. The Competition

MetricApogee TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.46B$3.39B$6.09B$10.48B
Dividend YieldN/A2.28%5.73%4.80%
P/E Ratio-13.3522.4484.5227.09
Price / SalesN/A267.64519.33179.64
Price / CashN/A46.5937.1661.22
Price / Book3.4610.4112.246.52
Net Income-$182.15M-$52.47M$3.32B$276.75M
7 Day Performance5.11%2.32%1.26%1.97%
1 Month Performance43.51%11.14%6.29%2.23%
1 Year Performance3.03%11.15%59.93%35.58%

Apogee Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APGE
Apogee Therapeutics
2.6985 of 5 stars
$55.15
+3.3%
$92.63
+68.0%
-1.9%$2.46BN/A-13.3591
MRUS
Merus
1.402 of 5 stars
$94.27
0.0%
$93.12
-1.2%
+83.4%$7.13B$56.23M-17.1437Short Interest ↓
RNA
Avidity Biosciences
2.5493 of 5 stars
$46.18
-1.7%
$68.32
+47.9%
-1.3%$6.86B$10.90M-12.97190News Coverage
Insider Trade
GRFS
Grifols
3.7638 of 5 stars
$9.61
-3.4%
$10.30
+7.2%
+12.3%$6.84B$7.81B8.2123,822
CYTK
Cytokinetics
3.8489 of 5 stars
$60.64
+6.4%
$76.64
+26.4%
+7.2%$6.82B$18.47M-11.89250Trending News
Insider Trade
RYTM
Rhythm Pharmaceuticals
2.8904 of 5 stars
$97.86
-1.2%
$106.64
+9.0%
+116.1%$6.58B$156.29M-32.51140News Coverage
Analyst Forecast
ABVX
Abivax
3.5043 of 5 stars
$86.67
+3.3%
$103.29
+19.2%
+795.9%$6.34BN/A0.0061Short Interest ↓
High Trading Volume
CRSP
CRISPR Therapeutics
2.2295 of 5 stars
$70.19
+3.6%
$71.50
+1.9%
+43.2%$6.16B$35M-12.93460Trending News
Analyst Forecast
Insider Trade
Analyst Revision
Gap Up
NUVL
Nuvalent
2.8066 of 5 stars
$83.85
-0.4%
$118.89
+41.8%
-9.4%$6.07BN/A-17.1140Trending News
Analyst Forecast
Insider Trade
Analyst Revision
AXSM
Axsome Therapeutics
4.73 of 5 stars
$119.94
-0.3%
$177.93
+48.4%
+37.1%$6.00B$495.03M-23.66380Analyst Revision
LEGN
Legend Biotech
3.0558 of 5 stars
$31.44
-1.9%
$74.22
+136.1%
-25.8%$5.92B$627.24M-35.732,609News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:APGE) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners